139 related articles for article (PubMed ID: 20374994)
1. Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia.
Hoang T
Sci Transl Med; 2010 Mar; 2(21):21ps10. PubMed ID: 20374994
[TBL] [Abstract][Full Text] [Related]
2. The molecular basis of Lmo2-induced T-cell acute lymphoblastic leukemia.
Curtis DJ; McCormack MP
Clin Cancer Res; 2010 Dec; 16(23):5618-23. PubMed ID: 20861166
[TBL] [Abstract][Full Text] [Related]
3. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal.
McCormack MP; Young LF; Vasudevan S; de Graaf CA; Codrington R; Rabbitts TH; Jane SM; Curtis DJ
Science; 2010 Feb; 327(5967):879-83. PubMed ID: 20093438
[TBL] [Abstract][Full Text] [Related]
4. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy: is IL2RG oncogenic in T-cell development?
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Nature; 2006 Sep; 443(7109):E5; discussion E6-7. PubMed ID: 16988660
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.
Grütz GG; Bucher K; Lavenir I; Larson T; Larson R; Rabbitts TH
EMBO J; 1998 Aug; 17(16):4594-605. PubMed ID: 9707419
[TBL] [Abstract][Full Text] [Related]
7. Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.
Ryan DP; Duncan JL; Lee C; Kuchel PW; Matthews JM
Proteins; 2008 Mar; 70(4):1461-74. PubMed ID: 17910069
[TBL] [Abstract][Full Text] [Related]
8. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Oncogene; 2002 Feb; 21(9):1309-15. PubMed ID: 11857074
[TBL] [Abstract][Full Text] [Related]
9. Identification of the key LMO2-binding determinants on Ldb1.
Ryan DP; Sunde M; Kwan AH; Marianayagam NJ; Nancarrow AL; Vanden Hoven RN; Thompson LS; Baca M; Mackay JP; Visvader JE; Matthews JM
J Mol Biol; 2006 May; 359(1):66-75. PubMed ID: 16616188
[TBL] [Abstract][Full Text] [Related]
10. Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia.
Grutz G; Forster A; Rabbitts TH
Oncogene; 1998 Nov; 17(21):2799-803. PubMed ID: 9840944
[TBL] [Abstract][Full Text] [Related]
11. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
12. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia.
Appert A; Nam CH; Lobato N; Priego E; Miguel RN; Blundell T; Drynan L; Sewell H; Tanaka T; Rabbitts T
Cancer Res; 2009 Jun; 69(11):4784-90. PubMed ID: 19487290
[TBL] [Abstract][Full Text] [Related]
13. Ldb1 is required for Lmo2 oncogene-induced thymocyte self-renewal and T-cell acute lymphoblastic leukemia.
Li L; Mitra A; Cui K; Zhao B; Choi S; Lee JY; Stamos DB; El-Khoury D; Warzecha C; Pfeifer K; Hardwick J; Zhao K; Venters B; Davé UP; Love PE
Blood; 2020 Jun; 135(25):2252-2265. PubMed ID: 32181817
[TBL] [Abstract][Full Text] [Related]
14. Early T cell differentiation lessons from T-cell acute lymphoblastic leukemia.
Tremblay CS; Hoang T; Hoang T
Prog Mol Biol Transl Sci; 2010; 92():121-56. PubMed ID: 20800819
[TBL] [Abstract][Full Text] [Related]
15. scid Thymocytes with TCRbeta gene rearrangements are targets for the oncogenic effect of SCL and LMO1 transgenes.
Chervinsky DS; Lam DH; Melman MP; Gross KW; Aplan PD
Cancer Res; 2001 Sep; 61(17):6382-7. PubMed ID: 11522630
[TBL] [Abstract][Full Text] [Related]
16. A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients.
Oram SH; Thoms JA; Pridans C; Janes ME; Kinston SJ; Anand S; Landry JR; Lock RB; Jayaraman PS; Huntly BJ; Pimanda JE; Göttgens B
Oncogene; 2010 Oct; 29(43):5796-808. PubMed ID: 20676125
[TBL] [Abstract][Full Text] [Related]
17. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
[TBL] [Abstract][Full Text] [Related]
18. Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia.
Van Vlierberghe P; Beverloo HB; Buijs-Gladdines J; van Wering ER; Horstmann M; Pieters R; Meijerink JP
Leukemia; 2008 Jul; 22(7):1434-7. PubMed ID: 18079736
[No Abstract] [Full Text] [Related]
19. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis.
Rabbitts TH; Axelson H; Forster A; Grutz G; Lavenir I; Larson R; Osada H; Valge-Archer V; Wadman I; Warren A
Leukemia; 1997 Apr; 11 Suppl 3():271-2. PubMed ID: 9209362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
